The fund will invest in shares of companies operating in the field of oncology (study, diagnosis, treatment, etc. of cancer) whose registered offices and/or principal activities are in the whole world. The fund seeks to achieve capital growth by investing in the principal assets traded, outperform the benchmark index and thus have a positive social long term impact, by selecting companies that take on certain societal challenges and that deploy resources in the fight against cancer.
Benchmark
MSCI World NR USD
Fondsgröße in Mio.
1.597,103
Gesamtkostenquote (TER)
1,95 %
Tracking Difference
2,1332
Ausschüttung
Thesaurierend